Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: An overview of dyslipidemia PART 06: Pipeline analysis PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by drug class • Statins • Cholesterol absorption inhibitors • Dyslipidemia injectables • Others PART 09: Geographical segmentation • Dyslipidemia drugs market in Americas • Dyslipidemia drugs market in EMEA • Dyslipidemia drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Impact of drivers on key customer segments • Market challenges • Impact of challenges on key customer segments PART 12: Market trends • Increasing use of statins • Combination therapies • Increased uptake of OTC drugs PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • Aegerion Pharmaceuticals • AstraZeneca • Merck • Pfizer • Sanofi • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Key customer segments Exhibit 02: Overview of phase III pipeline molecules in global dyslipidemia drugs market Exhibit 03: Pipeline analysis Exhibit 04: Global dyslipidemia drugs market snapshot 2016 Exhibit 05: Global dyslipidemia drugs market 2016-2021 ($ millions) Exhibit 06: Five forces analysis Exhibit 07: Global dyslipidemia drugs market by drug class Exhibit 08: Global statin market 2016-2021 ($ millions) Exhibit 09: Global cholesterol absorption inhibitors market 2016-2021 ($ millions) Exhibit 10: Global dyslipidemia injectables market 2016-2021 ($ millions) Exhibit 11: Global dyslipidemia drugs market by geography 2016 and 2021 Exhibit 12: Dyslipidemia drugs market revenue by geography 2016-2021 ($ millions) Exhibit 13: Market scenario in Americas Exhibit 14: Dyslipidemia drugs market in Americas 2016-2021 ($ millions) Exhibit 15: Market scenario in EMEA Exhibit 16: Dyslipidemia drugs market in the EMEA 2016-2021 ($ millions) Exhibit 17: Market scenario in APAC Exhibit 18: Dyslipidemia drugs market in APAC 2016-2021 ($ millions) Exhibit 19: Population aged 60 years and over: World and developed and developing regions (millions) Exhibit 20: Impact of drivers Exhibit 21: Impact of challenges Exhibit 22: Competitive structure analysis of global dyslipidemia drugs market 2016 Exhibit 23: Competitive analysis of global dyslipidemia drugs market 2016 Exhibit 24: Market penetration of various players in global dyslipidemia drugs market 2016 Exhibit 25: Aegerion Pharmaceuticals: Key highlights Exhibit 26: Aegerion Pharmaceuticals: Strength assessment Exhibit 27: Aegerion Pharmaceuticals: Strategy assessment Exhibit 28: Aegerion Pharmaceuticals: Opportunity assessment Exhibit 29: AstraZeneca: Key highlights Exhibit 30: AstraZeneca: Strength assessment Exhibit 31: AstraZeneca: Strategy assessment Exhibit 32: AstraZeneca: Opportunity assessment Exhibit 33: Merck: Key highlights Exhibit 34: Merck: Strength assessment Exhibit 35: Merck: Strategy assessment Exhibit 36: Merck: Opportunity assessment Exhibit 37: Pfizer: Key highlights Exhibit 38: Pfizer: Strength assessment Exhibit 39: Pfizer: Strategy assessment Exhibit 40: Pfizer: Opportunity assessment Exhibit 41: Sanofi: Key highlights Exhibit 42: Sanofi: Strength assessment Exhibit 43: Sanofi: Strategy assessment Exhibit 44: Sanofi: Opportunity assessment

AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla, CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, and Lupin Pharmaceuticals.